Similar articles

• No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?

  Doggrell SA. Doggrell SA. Expert Opin Pharmacother. 2017 Oct;18(14):1439-1442. doi: 10.1080/14656566.2017.1365838. Epub 2017 Aug 14. Expert Opin Pharmacother. 2017. PMID: 28799819
• Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.

  Eyvazian VA, Frishman WH. Eyvazian VA, et al. Cardiol Rev. 2017 Mar/Apr;25(2):43-52. doi: 10.1097/CRD.0000000000000137. Cardiol Rev. 2017. PMID: 28099220 Review.
• ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.

  Nissen SE, Pillai SG, Nicholls SJ, Wolski K, Riesmeyer JS, Weerakkody GJ, Foster WM, McErlean E, Li L, Bhatnagar P, Ruotolo G, Lincoff AM. Nissen SE, et al. JAMA Cardiol. 2018 May 1;3(5):401-408. doi: 10.1001/jamacardio.2018.0569. JAMA Cardiol. 2018. PMID: 29525816 Free PMC article.
• Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

  Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE. Nicholls SJ, et al. JAMA. 2011 Nov 16;306(19):2099-109. doi: 10.1001/jama.2011.1649. JAMA. 2011. PMID: 22089718 Clinical Trial.
• What have we learnt from the clinical outcomes trials with the cetrapibs?

  Doggrell SA. Doggrell SA. Curr Opin Lipidol. 2018 Aug;29(4):327-332. doi: 10.1097/MOL.0000000000000518. Curr Opin Lipidol. 2018. PMID: 29630000 Review.